Fidelity Select Biotechnology Portfolio (FBIOX)
Fund Assets | 3.81B |
Expense Ratio | 0.63% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 0.23 |
Dividend Yield | 1.31% |
Dividend Growth | 59.44% |
Payout Frequency | Semi-Annual |
Ex-Dividend Date | Apr 11, 2025 |
Previous Close | 17.07 |
YTD Return | -9.68% |
1-Year Return | -5.20% |
5-Year Return | 3.33% |
52-Week Low | 16.08 |
52-Week High | 22.47 |
Beta (5Y) | 0.62 |
Holdings | 187 |
Inception Date | Dec 16, 1985 |
About FBIOX
The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
Performance
FBIOX had a total return of -5.20% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.62%.
Top 10 Holdings
58.01% of assetsName | Symbol | Weight |
---|---|---|
AbbVie Inc. | ABBV | 13.05% |
Amgen Inc. | AMGN | 10.22% |
Krystal Biotech, Inc. | KRYS | 8.46% |
Gilead Sciences, Inc. | GILD | 7.04% |
Alnylam Pharmaceuticals, Inc. | ALNY | 4.68% |
Vertex Pharmaceuticals Incorporated | VRTX | 3.80% |
Regeneron Pharmaceuticals, Inc. | REGN | 3.31% |
Ascendis Pharma A/S | ASND | 2.57% |
argenx SE | ARGX | 2.54% |
UCB SA | UCB | 2.34% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Apr 11, 2025 | $0.062 | Apr 14, 2025 |
Dec 13, 2024 | $0.166 | Dec 16, 2024 |
Apr 12, 2024 | $0.063 | Apr 15, 2024 |
Dec 27, 2023 | $0.002 | Dec 28, 2023 |
Dec 1, 2023 | $0.078 | Dec 4, 2023 |
Dec 17, 2021 | $1.098 | Dec 20, 2021 |